- 1 day ago
- 7 min read
Key Takeaways |
China's National Medical Products Administration (NMPA) has approved as many or more CAR-T products for commercial use as the FDA has in the US, including the world's first CAR-T therapy approved for a solid tumor. |
The country also runs more registered CAR-T clinical trials than any other, and total cost of care is typically 70–80% lower than in the US for the same class of product. |
The best CAR-T hospitals in China include Lu Daopei Hospital, Peking University People's Hospital, Sun Yat-sen University Cancer Center, Nanfang Hospital, and the First Affiliated Hospital of Zhejiang University. |
Lu Daopei Hospital has enrolled more than 1,100 patients in CAR-T clinical trials since 2018, with a reported complete remission rate of approximately 90%. |
China's NMPA approved satricabtagene autoleucel in June 2026 for CLDN18.2-positive gastric cancer — the world's first CAR-T therapy approved for a solid tumor. |
Total cost of CAR-T care in China (product plus hospitalization) typically runs $80,000–$170,000 USD, compared to $650,000–$900,000+ for the equivalent total course of care in the US. |
Peking University People's Hospital's Institute of Hematology is led by Prof. Xiaojun Huang, developer of the "Beijing Protocol" for haploidentical stem cell transplant, now used internationally. |
Nanfang Hospital ran the pivotal trial of a third-generation CD19-CAR-T product for B-cell malignancies with central nervous system involvement, published in the Journal of Translational Medicine in 2025. |
Chinese CAR-T protocols commonly involve 3–5 weeks of inpatient monitoring after infusion, to manage cytokine release syndrome (CRS) and neurotoxicity risk in the first two to three weeks. |
Why China for CAR-T Therapy
China has become one of the most active countries in the world for CAR-T cell therapy research and treatment. The NMPA has approved a growing list of CD19- and BCMA-targeted CAR-T products for leukemia, lymphoma, and multiple myeloma, and in June 2026 approved the first CAR-T therapy in the world for a solid tumor — a CLDN18.2-targeted product for gastric cancer. China also has more registered CAR-T clinical trials than any other country, which gives patients access to product variations and treatment combinations not yet available elsewhere.
Cost is a second, separate factor. A commercial CAR-T infusion in the US typically costs $373,000–$475,000 for the drug product alone, with total cost of care (including hospitalization and management of side effects) commonly reaching $650,000–$900,000 or more. In China, total cost of care for the same class of product typically runs $80,000–$170,000, depending on the hospital, product, and length of hospitalization — see our CAR-T cost guide for a full breakdown by product and treatment stage.
Approval and cost don't tell you which hospital to choose, though — that depends on a center's specific experience with your disease subtype, and its track record managing CAR-T's most serious complications. For a broader look at how China compares to other CAR-T destinations, see our CAR-T treatment abroad guide.
The 5 Best CAR-T Hospitals in China
1. Lu Daopei Hospital (Beijing / Hebei)
Specialty: Pediatric and adult leukemia, lymphoma, and stem cell transplant, with CAR-T integrated into the treatment pathway.
Notable: 1,100+ patients enrolled in CAR-T clinical trials since 2018, with a reported complete remission rate of approximately 90%. Developed CD7-targeted CAR-T for T-cell leukemia and lymphoma. Performed 743 allogeneic stem cell transplants in 2023, roughly one-tenth of China's total annual transplant volume.
Estimated cost: $100,000–$150,000 USD. It covers CAR-T infusion, PET/CT diagnostics, bone marrow biopsy, and 28–45 days of hospitalization; final cost depends on the specific product and length of stay.
2. Peking University People's Hospital (Beijing)
Specialty: Complex and relapsed leukemia, with integration between CAR-T and stem cell transplant.
Notable: Home institution of Prof. Xiaojun Huang, developer of the "Beijing Protocol" for haploidentical (half-matched donor) stem cell transplant, now used in transplant centers internationally. Active trials in dual-target CD19/CD22 and CD19/CD20 CAR-T for patients who've relapsed after single-target CAR-T.
Estimated cost: $80,000–$160,000 USD, based on published citywide Beijing CAR-T pricing.
3. Sun Yat-sen University Cancer Center (Guangzhou)
Specialty: Lymphoma, with a dedicated Lymphoma Division that integrates CAR-T alongside chemotherapy, targeted therapy, and autologous stem cell rescue.
Notable: Research from its lymphoma program has been cited in Chinese national treatment consensus documents and NCCN guidelines, particularly for high-risk lymphoma subtyping and staging.
Estimated cost: $100,000–$150,000 USD.
4. Nanfang Hospital, Southern Medical University (Guangzhou)
Specialty: Leukemia and lymphoma, including cases with central nervous system involvement.
Notable: Led the pivotal trial of a third-generation CD19-CAR-T product for CNS-involved B-cell malignancies, published in the Journal of Translational Medicine in 2025. Hematology director Qifa Liu founded the 113-hospital South China Hematology Specialty Alliance.
Estimated cost: $100,000–$150,000 USD.
5. First Affiliated Hospital, Zhejiang University School of Medicine (Hangzhou)
Specialty: One of China's original CAR-T clinical research sites, active since the earliest trials in 2017.
Notable: Participating center in national multi-center pivotal CAR-T trials for relapsed/refractory leukemia.
Estimated cost: $100,000–$150,000 USD.
Comparing the Best CAR-T Hospitals in China
Hospital | CAR-T Experience | Disease Subtypes Covered | Estimated Cost (USD) |
Lu Daopei Hospital | 1,100+ patients in CAR-T clinical trials since 2018; ~90% reported complete remission rate | Leukemia, lymphoma, T-cell malignancies (CD7-CAR-T) | $90,000–$150,000 |
Peking University People's Hospital | Active dual-target CD19/CD22 and CD19/CD20 trials for patients who relapsed after prior CAR-T | Complex and relapsed leukemia | $80,000–$160,000 |
Sun Yat-sen University Cancer Center | Dedicated Lymphoma Division; research cited in Chinese national and NCCN treatment guidelines | Lymphoma, including high-risk subtypes | $100,000–$150,000 |
Nanfang Hospital | Led the 2025 pivotal trial of CD19-CAR-T for CNS-involved B-cell malignancies | Leukemia, lymphoma, CNS-involved B-cell malignancies | $100,000–$150,000 |
First Affiliated Hospital, Zhejiang University | CAR-T research site since 2017; participant in national multi-center pivotal trials | Relapsed/refractory leukemia |
For a full breakdown of what's included at each price point, see our CAR-T cost guide.
How to Get Started as an International Patient
International patients typically begin by sending recent PET-CT scans, pathology reports, and treatment history to a hospital's international department for eligibility review. This is what a physician uses to determine whether CAR-T is a realistic option for a specific case.
Before that step, many patients haven't yet gone through a formal second opinion and aren't sure what one actually involves. A second opinion isn't a diagnosis, and it doesn't replace a patient's local oncologist. It's a structured review of the case — records, prior treatment, current staging — by a physician at one of the hospitals above, who then explains directly whether the patient is likely to be a fit for CAR-T there, what treatment would involve, and what it would cost.
That review can happen over online meeting, with a physician at one or more of the hospitals above, before any decision about travel is made. It's a way to get a direct answer on eligibility and technical details from a physician at the hospital itself, rather than researching hospital websites and forming a plan based on published material alone.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
★★★★☆ Pongsakorn · Thailand · Feb 2025 · Verified “Kiki at Medebound is amazing — so professional and helpful! They got my video consultation with an MD Anderson expert set up super fast, within just 5 working days. I am so grateful for their support.” |
Frequently Asked Questions
How was this list of hospitals chosen?
Selection is based on documented CAR-T trial or commercial treatment volume and outcomes published in clinical trial registries or peer-reviewed journals — not accreditation alone, and not self-reported claims.
Does it matter which hospital I choose, or is CAR-T the same everywhere in China?
It matters. The underlying CAR-T products go through the same NMPA approval nationwide, but how well a hospital manages cytokine release syndrome and neurotoxicity, and how much experience it has with a specific disease subtype, varies meaningfully between centers.
Can international patients apply directly to these hospitals, or do I need a referral first?
Most accept direct applications through an international patient department or medical consierge company such as ChinaCureLink for fast-track service. A referral from a home-country oncologist isn't required, though sending existing records and pathology reports speeds up the eligibility review.
Is Lu Daopei Hospital only for children?
No. Lu Daopei treats both pediatric and adult patients, though it's particularly known for pediatric leukemia and lymphoma given its transplant and CAR-T bridging protocols.
My cancer subtype doesn't clearly match one hospital's specialty over another — how do I decide?
That's what the second-opinion consultation is for. A physician reviews the specifics of your case directly, rather than you having to match yourself to a hospital's general specialty description.
What happens if I'm not a good fit for CAR-T at any of these hospitals?
Physicians typically discuss alternatives — other cellular therapies, transplant, or conventional treatment — rather than simply declining the case.
We connect you with top physicians at these hospitals via a second-opinion consultation over Zoom first, to see whether you might be a good fit and to work through the technical details of your case.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
References
CD7 CAR-T bridging-to-transplant program, Lu Daopei — https://ashpublications.org/blood/article/142/Supplement%201/2155/502600/
Peking University People's Hospital, Institute of Hematology, Prof. Xiaojun Huang — https://newsen.pku.edu.cn/news_events/news/people/14015.html
Dual-target CD19/CD20 CAR-T trial, Peking University People's Hospital — https://clinicaltrials.gov/study/NCT07344818
Nanfang Hospital pivotal CNS-involvement CD19-CAR-T trial (J Transl Med, 2025) — https://clinicaltrials.gov/study/NCT04605666
Nanfang Hospital hematology outcomes and South China Hematology Specialty Alliance — https://www.nature.com/articles/d42473-022-00057-6
First Affiliated Hospital of Zhejiang University as CAR-T trial site — https://ashpublications.org/blood/article/140/Supplement%201/1598/487912/
Sun Yat-sen University Cancer Center Lymphoma Division — https://english.sysucc.org.cn/index_25.aspx?lcid=99
World-first solid-tumor CAR-T approval (satricabtagene autoleucel, gastric cancer) — https://www.insideprecisionmedicine.com/topics/oncology/solid-tumor-car-t-therapy-approved-in-china-a-world-first/
Comments